DK1771201T3 - Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom - Google Patents

Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom

Info

Publication number
DK1771201T3
DK1771201T3 DK05786347.4T DK05786347T DK1771201T3 DK 1771201 T3 DK1771201 T3 DK 1771201T3 DK 05786347 T DK05786347 T DK 05786347T DK 1771201 T3 DK1771201 T3 DK 1771201T3
Authority
DK
Denmark
Prior art keywords
oxalate
procedures
prevention
compositions
treatment
Prior art date
Application number
DK05786347.4T
Other languages
English (en)
Inventor
Harmeet Sidhu
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35510266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1771201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Application granted granted Critical
Publication of DK1771201T3 publication Critical patent/DK1771201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DK05786347.4T 2004-06-15 2005-06-15 Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom DK1771201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/868,242 US8486389B2 (en) 1997-05-23 2004-06-15 Compositions and methods for treating or preventing oxalate-related disease
PCT/US2005/021134 WO2005123116A2 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease

Publications (1)

Publication Number Publication Date
DK1771201T3 true DK1771201T3 (da) 2014-11-03

Family

ID=35510266

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14180734.7T DK2803366T3 (da) 2004-06-15 2005-06-15 Sammensætninger til behandling eller forebyggelse af oxalat-relateret sygdom
DK05786347.4T DK1771201T3 (da) 2004-06-15 2005-06-15 Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14180734.7T DK2803366T3 (da) 2004-06-15 2005-06-15 Sammensætninger til behandling eller forebyggelse af oxalat-relateret sygdom

Country Status (13)

Country Link
US (3) US8486389B2 (da)
EP (2) EP1771201B1 (da)
CN (2) CN101166421A (da)
CY (2) CY1115745T1 (da)
DK (2) DK2803366T3 (da)
ES (2) ES2692148T3 (da)
HK (1) HK1216080A1 (da)
LT (1) LT2803366T (da)
PL (2) PL2803366T3 (da)
PT (2) PT1771201E (da)
SI (2) SI1771201T1 (da)
TR (1) TR201815200T4 (da)
WO (1) WO2005123116A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
CN1578833B (zh) * 2001-10-05 2010-05-26 奥克斯赛拉公司 降低流体中草酸(盐)浓度的材料和方法
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1755655A4 (en) * 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
PT1962873E (pt) * 2005-12-14 2013-08-29 Oxthera Inc Composições farmacêuticas compreendendo bactérias redutoras de oxalato
ES2362897T3 (es) * 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
PT2046373E (pt) * 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
JP2012531186A (ja) * 2009-07-02 2012-12-10 オクステラ インテレクチュアル プロパティ エービー 組換えオキサレート分解酵素の精製及び単離並びにオキサレート分解酵素を含む噴霧乾燥粒子
DK2270138T3 (da) 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Oprensning og isolering af rekombinante oxalat-nedbrydende enzymer
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2504428A4 (en) * 2009-11-25 2013-09-25 Captozyme Llc METHODS AND COMPOSITIONS FOR TREATING OXALATE RELATED DISEASES
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
DK3003358T3 (da) 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc Sammensætninger og anordninger til dialyse
WO2015002588A1 (en) * 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes
EP3277099B9 (en) 2015-04-02 2024-05-29 Oxidien Pharmaceuticals, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
CA3023042A1 (en) * 2016-06-13 2017-12-21 Oxthera Intellectual Property Ab Compositions and methods for the treatment or prevention of oxalate-related disorders
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ，インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) * 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4888182A (en) 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5279827A (en) 1991-01-16 1994-01-18 Allegheny-Singer Research Institute Extract and pharmaceutical composition for treatment of calcium oxalate stone disease and viral infections
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP0673416A1 (en) 1992-11-30 1995-09-27 Zeneca Limited Oxalate decarboxylase
EP0693884A4 (en) 1993-04-16 1996-03-27 Mccormick & Co Inc ENCLOSURE COMPOSITIONS
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5554147A (en) 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
EP0764204B1 (en) 1994-05-18 2001-08-22 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US6214980B1 (en) 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
PT983076E (pt) * 1997-05-23 2010-01-05 Oxthera Inc Microrganismos de degradação de oxalato ou enzimas de degradação de oxalato para prevenir doenças relacionadas com oxalato
US20040120941A1 (en) 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US6080404A (en) 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
DE69940821D1 (de) 1998-10-09 2009-06-10 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
TR200103540T2 (tr) 1999-06-07 2002-04-22 Nanosphere Inc. Partikül kaplama yöntemleri ve bu şekilde üretilen partiküller.
DE10026541A1 (de) 2000-05-27 2001-11-29 Zeiss Carl Vorrichtung zur präzisen Positionierung eines Bauteils, insbesondere eines optischen Bauteiles
CN1578833B (zh) 2001-10-05 2010-05-26 奥克斯赛拉公司 降低流体中草酸(盐)浓度的材料和方法
US7407668B2 (en) 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
AU2003274918A1 (en) 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
EP1755655A4 (en) 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
PT1962873E (pt) 2005-12-14 2013-08-29 Oxthera Inc Composições farmacêuticas compreendendo bactérias redutoras de oxalato
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
US8486389B2 (en) 2013-07-16
SI2803366T1 (sl) 2018-12-31
PL2803366T3 (pl) 2018-12-31
DK2803366T3 (da) 2018-11-05
EP1771201A2 (en) 2007-04-11
EP1771201B1 (en) 2014-08-13
CY1120782T1 (el) 2019-12-11
US20190091268A1 (en) 2019-03-28
EP2803366A3 (en) 2015-02-18
US20040234514A1 (en) 2004-11-25
PL1771201T3 (pl) 2015-01-30
US20140030324A1 (en) 2014-01-30
PT2803366T (pt) 2018-11-06
EP1771201A4 (en) 2011-01-19
EP2803366B1 (en) 2018-08-01
LT2803366T (lt) 2018-12-27
WO2005123116A3 (en) 2008-01-03
ES2692148T3 (es) 2018-11-30
EP2803366A2 (en) 2014-11-19
US10653726B2 (en) 2020-05-19
HK1198922A1 (en) 2015-06-19
TR201815200T4 (tr) 2018-11-21
HK1216080A1 (zh) 2016-10-14
PT1771201E (pt) 2014-11-06
SI1771201T1 (sl) 2014-12-31
CY1115745T1 (el) 2017-01-25
CN104998253A (zh) 2015-10-28
CN101166421A (zh) 2008-04-23
WO2005123116A2 (en) 2005-12-29
US10149866B2 (en) 2018-12-11
ES2522898T3 (es) 2014-11-19

Similar Documents

Publication Publication Date Title
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK2026819T3 (da) Forebyggelse og/eller behandling af Alzheimers sygdom
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1793855T4 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1773361T3 (da) Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme og/eller infektioner og til forbedring af en intestinale funktionalitet
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK1773999T3 (da) Vaccine til forebyggelse og behandling af HIV-infektion
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
DK3199539T3 (da) Hidtil ukendte immunogene sammensætninger til forebyggelse og behandling af meningokoksygdom
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
EP1940423A4 (en) METHODS AND COMPOSITIONS OF TISSUE GENIUS
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK2463283T3 (da) Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2308900T3 (da) Immunogene sammensætninger og fremgangsmåder til anvendelse
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse